» Articles » PMID: 28511928

Rational Design of Nanoparticles Towards Targeting Antigen-presenting Cells and Improved T Cell Priming

Overview
Specialty Pharmacology
Date 2017 May 18
PMID 28511928
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination is a promising strategy to trigger and boost immune responses against cancer or infectious disease. We have designed, synthesized and characterized aliphatic-polyester (poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) to investigate how the nature of protein association (adsorbed versus entrapped) and polymer/surfactant concentrations impact on the generation and modulation of antigen-specific immune responses. The ability of the NP formulations to target dendritic cells (DC), be internalized and activate the T cells was characterized and optimized in vitro and in vivo using markers of DC activation and co-stimulatory molecules. Ovalbumin (OVA) was used as a model antigen in combination with the engraftment of CD4 and CD8 T cells, carrying a transgenic OVA-responding T cell receptor (TCR), to trace and characterize the activation of antigen-specific CD4 and CD8 lymph node T cells upon NP vaccination. Accordingly, the phenotype and frequency of immune cell stimulation induced by the NP loaded with OVA, isolated or in combination with synthetic unmethylated cytosine-phosphate-guanine (CpG) oligodeoxynucleotide (ODN) motifs, were characterized. DC-NP interactions increased with incubation time, presenting internalization values between 50 and 60% and 30-40%, in vitro and in vivo, respectively. Interestingly, animal immunization with antigen-adsorbed NP up-regulated major histocompatibility complex (MHC) class II (MHCII), while NP entrapping the antigen up-regulated MHCI, suggesting a more efficient cross-presentation. On the other hand, rather surprisingly, the surfactant used in the NP formulation had a major impact on the activation of antigen presenting cells (APC). In fact, DC collected from lymph nodes of animals immunized with NP prepared using poly(vinil alcohol) (PVA), as a surfactant, expressed significantly higher levels of CD86, MHCI and MHCII. In addition, those NP prepared with PVA and co-entrapping OVA and the toll-like receptor (TLR) ligand CpG, induced the most profound antigen-specific T cell response, by both CD4 and CD8 T cells, in vivo. Overall, our data reveal the impact of NP composition and surface properties on the type and extension of induced immune responses. Deeper understanding on the NP-immune cell crosstalk can guide the rational development of nano-immunotherapeutic systems with improved and specific therapeutic efficacy and avoiding off-target effects.

Citing Articles

Stick, Slide, or Bounce: Charge Density Controls Nanoparticle Diffusion.

Motezakker A, Greca L, Boschi E, Siqueira G, Lundell F, Rosen T ACS Nano. 2024; 18(42):28636-28648.

PMID: 39378149 PMC: 11503907. DOI: 10.1021/acsnano.4c05077.


PEI-Engineered Lipid@PLGA Hybrid Nanoparticles for Multimodal Delivery of Antigens and Immune Adjuvants to the Respiratory Mucosa.

Brusco S, Conte G, Corteggio A, Silvestri T, Spitaleri A, Brocca P Adv Healthc Mater. 2024; 13(32):e2402688.

PMID: 39258393 PMC: 11670295. DOI: 10.1002/adhm.202402688.


Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.

Deshmukh R, Sethi P, Singh B, Shiekmydeen J, Salave S, Patel R Pharmaceutics. 2024; 16(8).

PMID: 39204421 PMC: 11360117. DOI: 10.3390/pharmaceutics16081076.


Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.

Acurcio R, Kleiner R, Vaskovich-Koubi D, Carreira B, Liubomirski Y, Palma C Adv Sci (Weinh). 2024; 11(40):e2404159.

PMID: 39116324 PMC: 11515909. DOI: 10.1002/advs.202404159.


Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response.

Sobczak J, Barkovska I, Balke I, Rothen D, Mohsen M, Skrastina D Vaccines (Basel). 2024; 12(6).

PMID: 38932390 PMC: 11209419. DOI: 10.3390/vaccines12060661.